<DOC>
	<DOCNO>NCT00096174</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , cisplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Cetuximab may make tumor cell sensitive radiation therapy chemotherapy . Giving monoclonal antibody therapy together chemoradiotherapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab cisplatin together radiation therapy work treat patient locally advance regional stage IV head neck cancer remove surgery .</brief_summary>
	<brief_title>Phase II Study Concurrent C225 , Cisplatin Radiation Stage IV Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year progression-free survival patient unresectable locally advanced regional stage IV squamous cell undifferentiated carcinoma head neck treat cetuximab , cisplatin , definitive radiotherapy . Secondary - Determine response rate overall survival patient treat regimen . - Determine toxic effect regimen patient . - Correlate epidermal growth factor receptor ( EGFR ) expression immunohistochemistry , EGFR phosphorylation , map kinase , Akt , signal transducer activator transcription 3 ( STAT3 ) , tissue serum test toxicity regimen outcomes patient . OUTLINE : This multicenter study . Patients stratify accord tumor site ( hypopharynx vs. oropharynx vs. oral cavity vs. larynx ) , primary tumor stage ( T1-3 vs. T4 ) , nodal status ( N0 vs. N1 vs. N2-3 ) . - Cetuximab therapy : Patients receive initial load dose cetuximab IV 2 hour day 1 . Patients receive cetuximab IV 1 hour day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 . - Chemoradiotherapy : Beginning day 15 cetuximab therapy , patient undergo radiotherapy daily , 5 day week , least 7 week . Patients also receive cisplatin IV 1-2 hour day 15 , 36 , 57 . - Cetuximab maintenance therapy : After completion chemoradiotherapy , patient continue receive cetuximab IV 1 hour weekly 6-12 month . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 6 month 10 year . ACCRUAL : A total 69 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm squamous cell undifferentiated carcinoma head neck ( exclude nasopharynx , paranasal sinus , parotid gland ) Unresectable locally advance regional stage IV disease No evidence distant metastasis Must demonstrable primary tumor site Measurable disease Unresectable disease Meets follow criterion unresectable disease tumor site : Hypopharynx , meet 1 follow criterion : Extension across midline posterior pharyngeal wall Any evidence fixation cervical spine Larynx Direct subglottic extension ( &gt; 3cm ) surround muscle skin Oral cavity Lesion preclude functional reconstruction Base tongue , meet 1 follow criterion : Extension root tongue Patient refuse total glossectomy Tonsillar area , meet 1 follow criterion : Extension pterygoid area manifest xray trismus Extension across midline pharyngeal wall Direct extension soft tissue neck Unilateral neck node metastases fix carotid artery , mastoid , base skull , cervical spine tumor Patients require total glossectomy eligible Age &gt; =18 year ECOG Performance status 01 Adequate hematologic , renal , hepatic function obtain &lt; =4 week prior registration Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Alkaline phosphatase ≤ 3 time normal Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 3 time normal Bilirubin ≤ 1.5 mg/dL Creatinine ≤ 1.2 mg/dL OR creatinine clearance ≥ 50 mL/min Able tolerate fluid load At least 14 day since major surgery ( include dental extraction ) except percutaneous endoscopic gastrostomy ( PEG ) placement mediport placement Pregnant nursing Fertile patient use effective contraception Patients refuse surgery whose tumor technically resectable OR whose tumor unresectable medical reason eligible Disease metastases clavicle elsewhere ( M1 ) postoperative recurrence Prior excisional surgery head neck tumor Prior radiotherapy head neck region Prior chemotherapy Prior drug target epidermal growth factor receptor pathway Prior chimerized murine monoclonal antibody Active systemic infection Known allergy murine protein Severe chronic obstructive pulmonary disease require ≥ 3 hospitalization within past year Myocardial infarction within past 3 month Uncontrolled congestive heart failure Unstable uncontrolled angina Clinically apparent jaundice Postoperative recurrence Other malignancy within past 3 year except resect basal cell squamous cell skin cancer , carcinoma situ cervix , situ tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>